IL2 and acute myeloid leukemia: A 2012 prospective phase I/II clinical trial in patients with either renal cell carcinoma, malignant melanoma, or AML also showed that treatment with ZOL + IL‐2 is well‐tolerated and induced partial remission in 25% of AML patients.82